Project Grant R01HL176552
Award Date 9/15/25
Completion Date 5/31/30
Dollars Obligated $426K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Alabama, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $161,903 Project Grant to The Leland Stanford Junior University (Stanford University) on January 31, 2025 under the Cardiovascular Diseases Research (CFDA 93.837) program. The project aims to investigate risk stratification and outcomes across the spectrum of immune checkpoint inhibitor (ICI) cardiotoxicity subtypes. Specifically, the study will: (1) retrospectively examine cardiac and oncologic outcomes associated with ICI...
- The University of Louisville was awarded a $728,529 project grant by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant will fund research to investigate the relationship between the acute immune response and wound healing processes that occur following a myocardial infarction (MI). The project aims to characterize how "emergency granulopoiesis" - the acute increase in neutrophil production in response...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...
- The U.S. National Heart, Lung, and Blood Institute awarded a $803,768 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the J. David Gladstone Institutes, a non-profit biomedical research organization in California. The grant funding supports a research project titled "Chromatin Regulation of Immune Cells in Myocardial Inflammation", which aims to elucidate the role of the epigenetic regulator BRD4 in controlling monocyte differentiation and macrophage...
- The federal Project Grant award for "NUTRIENT SENSING OF APOPTOTIC CELLS BY MACROPHAGES RESOLVES INFLAMMATION, DRIVES ATHEROSCLEROSIS REGRESSION, AND PROMOTES FEATURES OF PLAQUE INSTABILITY" was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $659,441.00. The award supports research to define the mechanisms underlying the successive clearance of apoptotic cells by macrophages, with the goal of revealing new therapeutic...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,659,996.00 to the University of Southern California (USC) to investigate the role of the NF-kappaB modulator PDLIM2 in alveolar macrophages and its impact on lung innate immunity, inflammation, and diseases. The research aims to elucidate how alveolar macrophages, which are critical for lung defense, can promote lung cancer and increase vulnerability to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to understand how immune cells contribute to target organ damage in hypertension and autoimmune diseases. The $3,043,800 award to Vanderbilt University Medical Center will fund research projects focused on: 1) identifying T cell antigens and receptors associated with hypertension, systemic lupus erythematosus (SLE), and psoriasis; and 2) examining how dietary salt...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $402,911 Project Grant to The Trustees of Columbia University in the City of New York to develop a pericardial mRNA therapy for the treatment of myocardial infarction (heart attack). The research aims to create a new anti-inflammatory drug based on previous studies of stem cell derivatives for heart repair, which will be administered via minimally invasive...
- The National Heart, Lung, and Blood Institute (NHLBI), via the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $564,445 Project Grant to the University of Texas Health Science Center at Houston (UTHealth) to fund research on "Targeting Hypoxia-Inducible Factors (HIFs) for Heart and Lung Disease." The 6-year grant, starting on March 1, 2025 and ending on December 31, 2031, supports three complementary research projects focused on investigating the upstream regulation...